Table 2. TKI-induced change in QTc interval.
|
QTc interval (ms)
Median (IQR) |
||||
|---|---|---|---|---|
| TKI | n | Baseline | Therapy | P-value |
| Whole | 363 | 401 (388–415) | 415 (397–431) | <0.00001 |
| Sunitinib | 110 | 393 (380–410) | 406 (390–424) | <0.00001 |
| Vemurafenib | 67 | 401 (394–417) | 427 (415–442) | <0.00001 |
| Sorafenib | 52 | 400 (386–412) | 410 (394–425) | 0.0004 |
| Pazopanib | 46 | 402 (390–411) | 412 (395–431) | 0.079 |
| Imatinib | 41 | 410 (396–424) | 425 (410–439) | 0.002 |
| Erlotinib | 21 | 412 (398–430) | 421 (414–440) | 0.004 |
| Lapatinib | 16 | 413 (405–423) | 414 (397–428) | 0.982 |
| Gefitinib | 10 | 403 (396–417) | 409 (390–429) | 0.919 |
Abbreviations: IQR=interquartile range; n=number of patients within each TKI group; ΔQTc=median difference between QTc interval during TKI treatment and QTc interval at baseline; TKI=tyrosine kinase inhibitor. Bold values are statistically significant.